Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
4.580
-0.080 (-1.72%)
At close: Mar 19, 2026, 4:00 PM EDT
4.550
-0.030 (-0.66%)
Pre-market: Mar 20, 2026, 8:45 AM EDT
Opus Genetics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Opus Genetics stock have a consensus rating of "Strong Buy" and an average price target of $8.67, which forecasts a 89.30% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $12.
Price Target: $8.67 (+89.30%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 1 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +118.34% | Mar 16, 2026 |
| Wedbush | Wedbush | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +118.34% | Mar 12, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 → $11 | Strong Buy | Maintains | $9 → $11 | +140.17% | Mar 12, 2026 |
| BTIG | BTIG | Strong Buy Maintains $7 → $12 | Strong Buy | Maintains | $7 → $12 | +162.01% | Mar 2, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +52.84% | Jan 28, 2026 |
Financial Forecast
Revenue This Year
17.17M
from 14.20M
Increased by 20.94%
Revenue Next Year
19.15M
from 17.17M
Increased by 11.55%
EPS This Year
-0.46
from -0.80
EPS Next Year
-0.46
from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 31.5M | 45.1M | |||
| Avg | 17.2M | 19.2M | |||
| Low | 7.8M | 7.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 121.9% | 162.4% | |||
| Avg | 20.9% | 11.5% | |||
| Low | -44.8% | -54.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.35 | -0.23 | |||
| Avg | -0.46 | -0.46 | |||
| Low | -0.65 | -0.67 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.